Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
NCT03208660 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2019-04-11
Summary
This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.
Conditions
Interventions
- DRUG
-
Fycompa
Oral suspension
Sponsors & Collaborators
-
Eisai Inc.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-07
- Primary Completion
- 2019-03-15
- Completion
- 2019-03-15
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Fycompa in Catamenial Epilepsy
NCT05201703 ·Status: TERMINATED ·Phase: PHASE4
-
Fycompa Titration Intervals and Effects on Retention Rate
NCT03457129 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
NCT04202159 ·Status: COMPLETED
-
The Efficacy of Fycompa (Perampanel) in Children With Epilepsy
NCT04608799 ·Status: COMPLETED
-
Study for the Diagnosis and Treatment of Drug-resistant Focal Epilepsies
NCT06794606 ·Status: RECRUITING
-
Fenfluramine for Adult Dravet Patients
NCT05560282 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
NCT02736162 ·Status: COMPLETED
-
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
NCT00866775 ·Status: COMPLETED ·Phase: PHASE3
-
This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK
NCT05747001 ·Status: COMPLETED
-
Anti-epileptogenic Effects of Eslicarbazepine Acetate
NCT06597084 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GWP42006 in People With Focal Seizures - Part B
NCT02365610 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Resistant Epilepsy: Clinical and Genetic Study
NCT04166305 ·Status: UNKNOWN
-
Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
NCT01478035 ·Status: TERMINATED ·Phase: PHASE4
-
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
NCT00235755 ·Status: COMPLETED ·Phase: PHASE3
-
Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy
NCT04311242 ·Status: WITHDRAWN
-
Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy
NCT04308252 ·Status: WITHDRAWN
-
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
NCT04999046 ·Status: COMPLETED ·Phase: NA
-
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
NCT05419180 ·Status: COMPLETED ·Phase: PHASE4
-
The Modified Ketogenic Diet for the Treatment of Pharmacoresistant Epilepsy in Adults
NCT03425110 ·Status: UNKNOWN
-
Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy
NCT00986115 ·Status: WITHDRAWN ·Phase: NA
-
Human Epilepsy Project 2: Resistant Focal Seizures Study
NCT03531008 ·Status: COMPLETED
-
A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients
NCT00979004 ·Status: TERMINATED ·Phase: PHASE2
-
Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy
NCT05512130 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Phenytoin and Multidose Activated Charcoal
NCT00823264 ·Status: COMPLETED ·Phase: NA
-
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02495844 ·Status: COMPLETED ·Phase: PHASE2